Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
Since 2023, the Austrian Institute for Health Technology Assessment (AIHTA) is supporting the decisions of Austrian social insurance funds with short evidence syntheses as well as those of hospital providers with factsheets on new, expensive medicines. The aim is to support these decisions on medical services with evidence. The best available evidence from current reviews and clinical trials is summarised.
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 123 (February 2023)
Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 121 (February 2023)
Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer
Fact Sheet No. 122 (February 2023)
Oportuzumab monatox (Vicineum®) for Bladder cancer
Project / HTA-methods & steering instruments
Project leaders: Claudia Wild
Project team: Nikolaus Gregor-Patera
Duration: February 2023 – April 2023
AIHTA - Project „Transparency“
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 117 (February 2023)
Olaparib (Lynparza®) for mCRPC
Fact Sheet No. 118 (February 2023)
Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC
Fact Sheet No. 119 (February 2023)
Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC
Fact Sheet No. 120 (February 2023)
Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer
We are pleased to introduce our two new HSO Fact Sheets.
Fact Sheet No. 115 (December 2022)
Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Fact Sheet No. 116 (December2022)
Durvalumab (Imfinzi®) for Biliary tract cancer
Up to 20% of women and 10% of men suffer from mental health problems during pregnancy and in the first year after the birth of the child. Due to the potentially severe impact on parents and child, there is an urgent need for rapid and effective care. This scoping review provides an overview of international models for the prevention and care of perinatal mental health problems and describes their similarities and differences. The review is part of the FWF funded research project ‘Co-designing perinatal mental health support in Tyrol’.
QRs in dementia care are systems to support decision-makers and healthcare planners in developing optimal dementia care pathways while improving the quality of dementia care services and patient outcomes. The aim of the report was to analyse dementia QRs and to provide an overview of the quality indicators used including the underlying evidence. In addition, the empirical results from the identified dementia QRs, in combination with good registry practice from the literature, were embedded into a good practice framework.